Hormone therapy and the cardiovascular system

Maturitas

Volumn 43, Issue SUPPL., 2002, Pages 3-10

  Pines, Amos ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b Ramat Marpe Hospital   (Israel)

Author keywords

Cardioprotection; Cardiovascular system; Estrogens; HRT

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; SEX HORMONE;

ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL MEDICINE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; MEDICAL PRACTICE; MENOPAUSE; METABOLIC DISORDER; NONHUMAN; POPULATION RESEARCH; POSTMENOPAUSE; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; STROKE; TARGET ORGAN;

EID: 0037200668     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0378-5122(02)00143-3     Document Type: Review

References (54)

1. Grady D., Rubin S.M., Petiti D.B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 117:1992;1016-1037.
2. Bonita R. Epidemiology of stroke. Lancet. 339:1992;342-344.
3. Spencer C.P., Godsland I.F., Stevenson J.C. Is there a menopausal metabolic syndrome. Gynecol. Endocrinol. 11:1997;341-355.
4. Staessen J., Bulpitt C.J., Fagard R., et al. The influence of menopause on blood pressure. J. Hum. Hypertens. 3:1989;427-433.
5. Rosenthal T., Oparil S. Hypertension in women. J. Hum. Hypertens. 14:2000;691-704.
6. Matthews K.A., Kuller L.H., Sutton-Tyrrell K., Chang Y.-F. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in health women. Stroke. 32:2001;1104-1111.
7. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. J Am Med Assoc 1995;273:199-208.
8. Scuteri A., Bos A.J., Brant L.J., et al. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann. Intern. Med. 135:2001;229-238.
9. Mercuro G., Zoncu S., Pilia I., et al. Effects of acute administration of transdermal estrogen on postmenopausal women with systemic hypertension. Am. J. Cardiol. 80:1997;652-654.
10. Pines A., Fisman E.Z., Drory Y., et al. The effects of sublingual estradiol on left ventricular function at rest and exercise in postmenopausal women: anechocardiographic assessment. Menopause. 5:1998;79-85.
11. NAMS Consensus Opinion. Effects of menopause and estrogen replacement therapy or hormone replacement therapy in women with diabetes mellitus: Consensus opinion of the North American Menopause Society. Menopause 2000;7:87-95.
12. Manolio T.A., Furberg C.D., Shemanski I., et al. Association of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation. 88:1993;2163-2171.
13. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. New Engl. J. Med. 340:1999;1801-1811.
14. Davidson M.H., Maki K.C., Marx P., et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch. Intern. Med. 160:2000;3315-3325.
15. Walsh B.W., Paul S., Wild R.A., et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 85:2000;214-218.
16. Teede H.J., McGrath B.P., Smolich J.J., et al. Postmenopausal hormonereplacement therapy increases both coagulation activity and fibrinolysis. Arterioscler. Thromb. Vasc. Biol. 20:2000;1404-1409.
17. Mendelsohn M.E., Karas R.H. Mechanisms of disease: the protective effects of estrogen on the cardiovascular system. New Engl. J. Med. 340:1999;1801-1811.
18. Austin C.E. Chronic and acute effects of oestrogens on vascular contractility. J. Hypert. 18:2000;1365-1378.
19. Celermajer D.S., Sorensen K.E., Spiegelhalter D.J., et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J. Am. Coll. Cardiol. 24:1994;471-476.
20. Pines A., Fisman E.Z., Levo Y., et al. The effects of hormone replacement therapy in normal post-menopausal women: measurement of Doppler-derived parameters of aortic flow. Am. J. Obstet. Gynecol. 164:1991;806-812.
21. Pines A., Fisman E.Z., Drory Y., et al. Menopause-induced changes in Doppler-derived parameters of aortic flow in healthy women. Am. J. Cardiol. 69:1992;1104-1106.
22. Pines A., Fisman E.Z., Levo Y., et al. Menopause-induced changes in left ventricular wall thickness. Am. J. Cardiol. 72:1993;240-241.
23. Rosano G.M.C., Sarrel P.M., Poole-Wilson P.A., et al. Beneficial effect of oestrogen on exercise-induced myocardial ischemia in women with coronary artery disease. Lancet. 342:1993;133-136.
24. Hong M.K., Romm P.A., Reagen K., Green C.E., Rackley C.E. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am. J. Cardiol. 69:1992;176-178.
25. Clarkson T.B., Anthony M.S., Morgan T.M. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J. Clin. Endocrinol. Metab. 86:2001;41-47.
26. Dobs A.S., Nieto F.J., Szklo M., et al. Risk factors for popliteal and carotid wall thickness in the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Epidemiol. 150:1999;1055-1067.
27. Joakimsen O., Bonaa K.H., Stensland-Bugge E., Jacobsen B.K. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis. The Tromso study. J. Clin. Epidemiol. 53:2000;525-530.
28. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. New Engl. J. Med. 343:2000;522-529.
29. Angerer P., Stork S., Kothny W., Schmitt P., von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21:2001;262-268.
30. Hodis H.N., Mack W.J., Lobo R.A., et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 135:2001;939-953.
31. Barrett-Connor E., Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu. Rev. Public Health. 19:1998;55-72.
32. Sourander L., Rajala T., Raiha I., et al. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet. 352:1998;1965-1969.
33. Grodstein F., Manson J.E., Colditz G.A., et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133:2000;933-941.
34. Rodriguez C., Calle E.E., Patel A.V., et al. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am. J. Epidemiol. 153:2001;145-152.
35. Hemminki E., McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. Br. Med. J. 315:1997;149-153.
36. Hu F.B., Stampfer M.J., Manson J.E., et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. New Engl. J. Med. 343:2000;530-537.
37. Sullivan J.M., Vander Zwaag R., et al. Estrogen replacement and coronary artery disease: effect in survival in postmenopausal women. Arch. Intern. Med. 150:1990;2557-2562.
38. Sullivan J.M., El-Zeky F., Vander Zwaag R., Ramanathan K.B. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am. J. Cardiol. 79:1997;847-850.
39. O'Keefe J.H., Kim S.C., Hall R.R., et al. Estrogen replacement therapy after coronary angioplasty in women. J. Am. Coll. Cardiol. 29:1997;1-5.
40. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary artery disease in post menopausal women. J. Am. Med. Assoc. 280:1998;605-613.
41. Speroff L. Postmenopausal hormone therapy and coronary heart disease: clinical implications of recent randomized trial results. Maturitas. 35:2000;91-97.
42. Grodstein F., Manson J.E., Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health study. Ann. Intern. Med. 135:2001;1-8.
43. Heckbert S.R., Kaplan R.C., Weiss N.S., et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch. Intern. Med. 161:2001;1709-1713.
44. Alexander K.P., Newby L.K., Hellkamp A.S., et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J. Am. Coll. Cardiol. 38:2001;1-7.
45. Shlipak M.G., Angeja B.G., Go A.S., et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation. 104:2001;2300-2304.
46. Hurn P.D., Macrae I.M. Estrogen as a neuroprotectant in stroke. J. Cereb. Blood. Flow. Metab. 20:2000;631-652.
47. Wise P.M., Dubal D.B., Wilson M.E., Rau S.W., Bottner M. Minireview: neuroprotective effects of estrogen - new insights into mechanism of action. Endocrinology. 142:2001;969-973.
48. Paganini-Hill A. Hormone replacement therapy and stroke: risk, protection or no effect. Maturitas. 38:2001;243-261.
49. Simon J.A., Hsia J., Cauley J.A., et al. Postmenopausal hormone use and the risk of stroke. The Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 103:2001;638-642.
50. Viscoli C.M., Brass L.M., Kernan W.N., et al. A clinical trial of estrogen replacement therapy after ischaemic stroke. New Engl. J. Med. 345:2001;1243-1249.
51. Mosca L., Collins P., Herrington D.M., et al. AHA scientific statement. Hormone replacement therapy and cardiovascular disease. Circulation. 104:2001;499-503.
52. Guest Editorial and Critical Comments. The AHA guidelines on hormone replacement therapy and cardiovascular disease. Maturitas 2001;40:1-15.
53. Mendelsohn ME, Karas RH. The time has come to stop letting the HERS tale wag the dogma. Circulation 2001;104:2256-2259
54. Moerman C.J., Van Hout B.A., Bonneux L., Witteman J.C.M. Postmenopausal hormone therapy: less favorable risk-benefit ratios in healthy Dutch population. Ann. Intern. Med. 248:2000;143-150.